Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics has announced a board resolution to convene its 14th Annual General Meeting (AGM) of Shareholders on March 14, 2025, at 09:00 KST at Songdo Convensia. Proposed agenda items include the approval of FY2024 financial statements, amendments to the articles of incorporation, appointments of directors and audit committee members, and approval of director remuneration limits.
📊 [Key Disclosure Details & Financial Figures]
- Disclosure Title: Decision to Convene General Meeting of Shareholders
- Meeting Type: Annual General Meeting (AGM)
- Date & Time: March 14, 2025, at 09:00 KST
- Location: Room 113, 1st Floor, Songdo Convensia (123 Central-ro, Yeonsu-gu, Incheon)
- Board Resolution Date: February 12, 2025 (4 independent directors present)
- Proposed Agenda Items:
- Report Items: Transactions with related parties, Audit report, Business report, Assessment of internal accounting control system operations
- Voting Items:
- Item 1: Approval of FY2024 (Jan 1, 2024 – Dec 31, 2024) Financial Statements
- Item 2: Amendments to the Articles of Incorporation
- Item 3: Appointment of Directors
- Item 3-1: Appointment of Executive Director Seung-ho Yoo (New, 3-year term)
- Item 3-2: Appointment of Independent Director Ho-seung Lee (New, 3-year term)
- Item 4: Appointment of Independent Director Chang-woo Lee as Audit Committee Member (Re-appointment, 3-year term)
- Item 5: Appointment of Ho-seung Lee as Audit Committee Member (New, 3-year term)
- Item 6: Approval of Director Remuneration Limit
- Details of Director Nominees:
- Seung-ho Yoo (Executive Director Nominee): Head of Corporate Support Center at Samsung Biologics (New, 3-year term)
- Ho-seung Lee (Independent Director & Audit Committee Nominee): Former Chief of Staff for Policy to the President, Former 1st Vice Minister of Economy and Finance (New, 3-year term)
- Chang-woo Lee (Independent Director & Audit Committee Nominee): Professor Emeritus at Seoul National University, Current Independent Director and Audit Committee Chair at Samsung Biologics (Re-appointment, 3-year term)
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Monitoring AGM Execution and Voting Results
This disclosure provides notice of Samsung Biologics’ board decision to schedule its 14th AGM on March 14, 2025, and details the proposed agenda items.
Tracking the voting outcomes—specifically regarding the approval of financial statements and director appointments—is essential.
Relevant details can be verified in subsequent official disclosures regarding the AGM results and in upcoming periodic filings (Annual Report).
📢 Disclaimer & Source Notice
Source: This content was structured and regenerated based on official data submitted to the Financial Supervisory Service’s DART system.
Investment Risk Warning: This content is provided solely for informational and educational purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
